Jaimy Lee is a Deputy Editor at Endpoints. With over 15 years of experience, she specializes in healthcare and pharmaceuticals, covering topics such as health news, consumer health, and wellness programs. Her work has been recognized by prestigious organizations and she has been featured in outlets including Yahoo Finance, Yahoo News, and MarketWatch.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Jaimy Lee's coverage focuses on healthcare and pharmaceuticals, with a significant emphasis on investment analysis and private sector announcements. Given the nature of her articles, she is likely to be receptive to pitches from individuals or organizations involved in drug development, biotech partnerships, or financing within the healthcare and pharmaceutical industries.
Her focus on press releases and citing data indicates that she values accuracy and official information. Pitches should highlight well-supported facts relevant to the topics covered such as new drug developments, business collaborations, or financial trends specific to the healthcare sector.
While Jaimy Lee does not specify a geographic focus in her article titles, it is important for potential sources reaching out to consider her coverage spans international markets within the healthcare and pharmaceutical sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jaimy Lee
That means millions more Americans may get access to Lilly’s new GLP-1 pill Foundayo or the GLP-1 injection Zepbound.
By: Jaimy Lee
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug
By: Jaimy Lee
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug
By: Jaimy Lee
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug
By: Jaimy Lee
About 50 million Americans aren’t getting screened for colon cancer at a time when colon-cancer rates are rising.
By: Jaimy Lee
There is a new wave of weight-loss therapies in development that aim to be better than the existing GLP-1s.
It has remained a top choice among Americans trying to lose weight even after the launch of Foundayo, Eli Lilly’s GLP-1 pill.
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
By: Jaimy Lee
Starting July 1, Medicare beneficiaries will have access to weight-loss drugs for the first time. There are some unique factors they should consider.
Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.
